Off-label Drug Marketing of Antipsychotic Drugs for Children?

A new study found a 62% increase in the number of children ages 3 to 18 who are enrolled in Medicaid taking antipsychotic drugs in the last ten years.  The number of children taking such antipsychotics was 354,000 in 2007.  Science Daily reports: Increased antipsychotic use was observed across a wide range of mental health diagnoses, and was particularly high for children with ADHD or conduct disorder, although the FDA has not approved the drugs to treat these conditions in children. In total, 65% of children prescribed antipsychotics in 2007 were using the drugs “off-label,” or...

read more

GlaxoSmithKline to Pay $3 Billion in Pharmaceutical Whistleblower Case

Pharmaceutical company GlaxoSmithKline has agreed to pay $3 billion in fines to the government in a pharmaceutical whistleblower case.  This is the largest pharmaceutical fraud settlement to date, and brings whistleblower lawsuit settlements to a total of $10 billion for 2012.  Whistleblowers get a share of these settlements as a reward for reporting fraud under the False Claims Act. The pharmaceutical whistleblowers were four GSK employees, including a vice president and a senior marketing development manager.  The pharmaceutical fraud involved GSK’s conduct regarding Paxil,...

read more